Solasia Pharma K.K. revised consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue of ¥1,150 million, operating loss of ¥2,350 million, loss attributable to owners of parent of ¥2,450 and basic loss per share of ¥14.60 compared to previous guidance of revenue of ¥1,150 million, operating loss of ¥2,150 million, loss attributable to owners of parent of ¥2,250 and basic loss per share of ¥13.41.